Open AccessClinical presentation, case management and outcomes for the first 32 COVID-19 patients in Nigeria
Author(s) -
Abimbola Bowale,
Akin Abayomi,
Jide Idris,
Sunday Aremu Omilabu,
Ismail Abdus-Salam,
Busayo Adebayo,
Folarin Opawoye,
Ore Finnih-Awokoya,
Emmanuella Zamba,
Hussein Abdur-Razzaq,
O Erinoso,
Tosin Onasanya,
Patrick Otim Ramadan,
Sam Nyenyi,
Evaristus Aniaku,
Muhammad Shakir Balogun,
Oyeladun Okunromade,
Olusola Adedeji Adejumo,
Sunday Adesola,
Tope Ogunniyan,
Mobolanle Balogun,
Akin Osibogun
Publication year - 2020
Publication title -
the pan african medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.287
H-Index - 30
ISSN - 1937-8688
DOI - 10.11604/pamj.supp.2020.35.2.23262
Subject(s) - medicine , asymptomatic , retrospective cohort study , covid-19 , population , lopinavir , pandemic , medical record , pediatrics , disease , emergency medicine , infectious disease (medical specialty) , environmental health
Success in curtailing the pandemic coronavirus disease (COVID-19) depends largely on a sound understanding of the epidemiologic and clinical profile of cases in a population as well as the case management approach. This study documents the presenting characteristics, treatment modalities and outcomes of the first 32 COVID-19 patients in Nigeria. Methods This retrospective study used medical records of the first 32 patients admitted and discharged from the Mainland Hospital, Lagos State, southwest Nigeria between February 27 and April 6, 2020. The outcomes of interest were death, promptness of admission process and duration of hospitalization. Results The mean age of the patients was 38.1 years (SD: 15.5) and 66% were male. Three-quarters (75%) of the patients presented in moderately severe condition while 16% were asymptomatic. The most common presenting symptoms were fever (59%) and dry cough (44%). The mean time between a positive test result and admission was 1.63 days (SD: 1.31). Almost all (97%) the patients were treated with lopinavir-ritonavir with no recorded death. The median duration of hospital stay was 12 days (IQR: 9-13.5). Conclusion In this preliminary analysis of the first COVID-19 cases in Nigeria, clinical presentation was mild to moderate with no mortality. Processes to improve promptness of admission and reduce hospital stay are required to enhance the response to COVID-19 in Nigeria.